Send to

Choose Destination
See comment in PubMed Commons below
J Affect Disord. 2007 Nov;103(1-3):83-90. Epub 2007 Feb 9.

A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.

Author information

  • 1Behavioral Health and Clinical Neurosciences Division, Portland VA Medical Center, Oregon, United States.

Erratum in

  • J Affect Disord. 2009 Feb;113(1-2):201.



Interferon-alpha-(IFN-alpha) induced depression presents a challenge when treating patients with the hepatitis C virus (HCV). Depression occurs in approximately one-third of patients during antiviral therapy and can lead to reduction in treatment dosage or discontinuation of treatment, thus reducing the likelihood of clearing HCV infection. This study examined the efficacy of paroxetine in preventing the development of depression during antiviral therapy.


In a double-blind, placebo-controlled study, 33 patients with HCV were randomly assigned to paroxetine or placebo prior to antiviral therapy. Patients were evaluated for psychiatric symptoms prior, during, and six months after antiviral therapy.


The rate of IFN-alpha-induced depression for the entire sample was 33.3%. The prophylactic use of paroxetine did not decrease the likelihood of IFN-alpha-induced depression (35.7% in the paroxetine group vs. 31.6% in the placebo group). However, in 10 of 11 patients who developed IFN-alpha-induced depression and entered the rescue arm of the study, open-label treatment with paroxetine helped reduce symptoms of depression. Group assignment did not appear to impact antiviral therapy completion rates, as a similar proportion of patients from each group completed treatment.


The antiviral treatment was changed during the trial and aspects of the sample limit the generalizability of the results.


A prophylactic approach to interferon-alpha-induced depression may not be indicated in patients with HCV infection.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk